In contrast to the earlier report, letrozole was clinically effective in the 202 patients with ER+ tumours, irrespective of the HER2 status (71% in both subsets; P = 0.98), suggesting that they are sensitive to short-term oestrogen deprivation therapy. This evidence concerns the gene ERBB2 and neoplasm.